

First reports of adverse drug reactions

© Springer Nature Switzerland AG 2019

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of

adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

Table 1 First published reports of adverse drug reactions recently identified by *Reactions Weekly*

Drug and adverse reaction	References
Antithymocyte-globulin: reversible cerebral vasoconstriction syndrome (serious)	Yamamoto A, Meguri Y, Fukuda A, et al. A case of reversible cerebral vasoconstriction syndrome developing during treatment of adult aplastic anemia. <i>Ann Hematol.</i> 2019;98(2):511–3. https://doi.org/10.1007/s00277-018-3430-6
Aripiprazole abuse/overdose: second degree atrioventricular following a suicide attempt (serious)	Russo L, Rizzo A, Di Vincenzo A, et al. Aripiprazole overdose and transient 2:1 second degree atrioventricular block: only a coincidence? <i>Curr Drug Saf.</i> 2019. https://doi.org/10.2174/1574886314666190119120657
Epinephrine/mepivacaine: retinal toxicity following accidental intravitreal administration (serious)	López-Herrero F, Sánchez-Vicente JL, Monge-Esquivel J, et al. Retinal toxicity after accidental intravitreal injection of mepivacaine and adrenaline [in Spanish]. <i>Arch Soc Esp Oftalmol.</i> 2018;93(3):143–6. https://doi.org/10.1016/j.oftal.2017.06.014
Eribulin: tumour lysis syndrome (serious)	Pabon C, Esnakula AK, Daily K. Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma. <i>BMJ Case Rep.</i> 2018;11(1). http://doi.org/10.1136/bcr-2018-224576
Exenatide: drug-induced immune thrombocytopenia (serious)	Vallatharasu Y, Hayashi-Tanner Y, Polewski PJ, et al. Severe, prolonged thrombocytopenia in a patient sensitive to exenatide. <i>Am J Hematol.</i> 2019;94(3):E78–E80. https://doi.org/10.1002/ajh.25381
Fulvestrant: fixed drug eruption (serious)	Broche C, Pralong P, Gil H, et al. Fixed drug eruption caused by fulvestrant confirmed by skin tests: first case. <i>Contact Dermatitis.</i> 2019;80(3):184–6. https://doi.org/10.1111/cod.13161
Methylprednisone: Orf disease ^a	Kostopoulos M, Gerodimos CA, Batsila E, et al. Orf disease in a patient with rheumatoid arthritis. <i>Mediterr J Rheum.</i> 2018;29(2):89–91. https://doi.org/10.31138/mjr.29.2.89
Pembrolizumab: prurigo nodularis (serious)	Fattore D, Panariello L, Annunziata MC, et al. Prurigo nodularis and pembrolizumab: a therapeutic challenge. <i>Eur J Cancer.</i> 2019;110:8–10. https://doi.org/10.1016/j.ejca.2019.01.012
Valsartan: malignant melanoma (serious)	Tchernev G, Temelkova I. Valsartan induced melanoma?! First description in medical literature! <i>Open Access Maced J Med Sci.</i> 2018;6(12):2378–80. https://doi.org/10.3889/oamjms.2018.517

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage

^aRare viral infection, which affects patients involved in the care of livestock. Also known as ecthyma contagiosum, contagious pustular dermatitis and infectious euphoria